| abstract |
Crystalline forms and/or polymorphs of the compounds having structure (I), including tautomeric and zwitterionic forms, are provided: . Methods associated with the preparation and use of such polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided is a process for preparing a compound having formula (I) or a salt, tautomer or zwitterionic form thereof. |